| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Acute GVHD prophylaxis—atorvastatin for donor and recipient
|
Gilbert, Judith A
|
|
2013
|
|
13 |
p. e589-
1 p.
|
artikel
|
| 2 |
Addition of interleukin-6 inhibition with tocilizumab to standard graft-versus-host disease prophylaxis after allogeneic stem-cell transplantation: a phase 1/2 trial
|
Kennedy, Glen A
|
|
2014
|
|
13 |
p. 1451-1459
|
artikel
|
| 3 |
Addressing the burden of cancer in the Gulf
|
The Lancet Oncology,
|
|
2014
|
|
13 |
p. 1407
|
artikel
|
| 4 |
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial
|
Bruix, Jordi
|
|
2015
|
|
13 |
p. 1344-1354
11 p.
|
artikel
|
| 5 |
Adjuvant sorafenib for liver cancer: wrong stage, wrong dose
|
Kelley, Robin Kate
|
|
2015
|
|
13 |
p. 1279-1281
3 p.
|
artikel
|
| 6 |
Adjuvant trastuzumab improves survival in early breast cancer
|
Brower, Vicki
|
|
2014
|
|
13 |
p. e589
|
artikel
|
| 7 |
Adjuvant treatment for resected pancreatic adenocarcinoma—still an unresolved issue
|
Leung, John
|
|
2013
|
|
13 |
p. e583-e584
nvt p.
|
artikel
|
| 8 |
An oral proteasome inhibitor for multiple myeloma
|
Pratt, Guy
|
|
2014
|
|
13 |
p. 1417-1418
|
artikel
|
| 9 |
A practice-changing step forward in germ-cell cancer?
|
Lorch, Anja
|
|
2014
|
|
13 |
p. 1409-1410
|
artikel
|
| 10 |
Arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia in all risk groups (AML17): results of a randomised, controlled, phase 3 trial
|
Burnett, Alan K
|
|
2015
|
|
13 |
p. 1295-1305
11 p.
|
artikel
|
| 11 |
A tale of regeneration
|
Brogan, Caroline
|
|
2015
|
|
13 |
p. 1293-
1 p.
|
artikel
|
| 12 |
Australian HPV vaccination programme yields results
|
Howe, Megan
|
|
2014
|
|
13 |
p. e591
|
artikel
|
| 13 |
Autologous haemopoietic stem-cell transplantation followed by allogeneic or autologous haemopoietic stem-cell transplantation in patients with multiple myeloma (BMT CTN 0102): a phase 3 biological assignment trial
|
Krishnan, Amrita
|
|
2011
|
|
13 |
p. 1195-1203
9 p.
|
artikel
|
| 14 |
Axitinib in advanced renal-cell carcinoma
|
Yousaf, Nadia
|
|
2013
|
|
13 |
p. 1245-1246
2 p.
|
artikel
|
| 15 |
Axitinib versus sorafenib as first-line therapy in patients with metastatic renal-cell carcinoma: a randomised open-label phase 3 trial
|
Hutson, Thomas E
|
|
2013
|
|
13 |
p. 1287-1294
8 p.
|
artikel
|
| 16 |
Biomarker for high-risk patients with stage II colon cancer
|
Watanabe, Toshiaki
|
|
2013
|
|
13 |
p. 1247-1248
2 p.
|
artikel
|
| 17 |
Bitumens and bitumen emissions, and some heterocyclic polycyclic aromatic hydrocarbons
|
Lauby-Secretan, Beatrice
|
|
2011
|
|
13 |
p. 1190-1191
2 p.
|
artikel
|
| 18 |
Blurring of boundaries in the doctor–patient relationship
|
Fallowfield, Lesley
|
|
2014
|
|
13 |
p. 1423-1424
|
artikel
|
| 19 |
Brentuximab vedotin combined with ABVD or AVD for patients with newly diagnosed Hodgkin's lymphoma: a phase 1, open-label, dose-escalation study
|
Younes, Anas
|
|
2013
|
|
13 |
p. 1348-1356
9 p.
|
artikel
|
| 20 |
Cannabis and cancer: reality or pipe dream?
|
Cathcart, Paul
|
|
2015
|
|
13 |
p. 1291-1292
2 p.
|
artikel
|
| 21 |
Can we improve ABVD in Hodgkin's lymphoma?
|
Gisselbrecht, Christian
|
|
2013
|
|
13 |
p. 1254-1256
3 p.
|
artikel
|
| 22 |
Carcinogenicity of fluoro-edenite, silicon carbide fibres and whiskers, and carbon nanotubes
|
Grosse, Yann
|
|
2014
|
|
13 |
p. 1427-1428
|
artikel
|
| 23 |
Cetuximab and non-small-cell lung cancer: end of the story?
|
Rossi, Antonio
|
|
2013
|
|
13 |
p. 1251-1253
3 p.
|
artikel
|
| 24 |
Changes in bone mineral density at 3 years in postmenopausal women receiving anastrozole and risedronate in the IBIS-II bone substudy: an international, double-blind, randomised, placebo-controlled trial
|
Sestak, Ivana
|
|
2014
|
|
13 |
p. 1460-1468
|
artikel
|
| 25 |
Chromoplexy and hypoxic microenvironment drives prostate cancer
|
Ballas, Leslie K
|
|
2014
|
|
13 |
p. 1419-1421
|
artikel
|
| 26 |
CIN excision and preterm birth risk
|
Burki, Talha Khan
|
|
2014
|
|
13 |
p. e592
|
artikel
|
| 27 |
Combination boosts survival for metastatic melanoma
|
Tanday, Sanjay
|
|
2014
|
|
13 |
p. e592
|
artikel
|
| 28 |
Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial
|
Grob, Jean Jacques
|
|
2015
|
|
13 |
p. 1389-1398
10 p.
|
artikel
|
| 29 |
Controversy about UK assisted dying bill
|
Burki, Talha Khan
|
|
2015
|
|
13 |
p. e483-
1 p.
|
artikel
|
| 30 |
Cord blood meets its match
|
Gratwohl, Alois
|
|
2011
|
|
13 |
p. 1177-1178
2 p.
|
artikel
|
| 31 |
Corrections to multiple conflicts of interest statements
|
|
|
2015
|
|
13 |
p. e480-
1 p.
|
artikel
|
| 32 |
Correction to Lancet Oncol 2015; 16: 1289
|
|
|
2015
|
|
13 |
p. e480-
1 p.
|
artikel
|
| 33 |
Correction to Lancet Oncol 2015; 16: 1338
|
|
|
2015
|
|
13 |
p. e480-
1 p.
|
artikel
|
| 34 |
Correction to Lancet Oncol 2014; 15: 310, 311
|
|
|
2014
|
|
13 |
p. e587
|
artikel
|
| 35 |
Correction to Lancet Oncol 2014; 15: 1464
|
|
|
2014
|
|
13 |
p. e587
|
artikel
|
| 36 |
Correction to Lancet Oncol 2014; 15: 1280
|
|
|
2014
|
|
13 |
p. e587
|
artikel
|
| 37 |
Correction to Lancet Oncol 2015; 16: e434
|
|
|
2015
|
|
13 |
p. e480-
1 p.
|
artikel
|
| 38 |
Correction to Lancet Oncol 2014; 15: e395–403
|
|
|
2014
|
|
13 |
p. e587
|
artikel
|
| 39 |
Correction to Lancet Oncol 2014; 15: e591
|
|
|
2014
|
|
13 |
p. e587
|
artikel
|
| 40 |
CRC risk knowledge does not affect screening compliance
|
Bagcchi, Sanjeet
|
|
2014
|
|
13 |
p. e588
|
artikel
|
| 41 |
CT screening for lung cancer: countdown to implementation
|
Field, John K
|
|
2013
|
|
13 |
p. e591-e600
nvt p.
|
artikel
|
| 42 |
Curing Cancer
|
Norton, Emma
|
|
2014
|
|
13 |
p. 1432
|
artikel
|
| 43 |
Dacomitinib: another option for EGFR-mutant lung cancer?
|
Mitsudomi, Tetsuya
|
|
2014
|
|
13 |
p. 1408-1409
|
artikel
|
| 44 |
Dacomitinib as first-line treatment in patients with clinically or molecularly selected advanced non-small-cell lung cancer: a multicentre, open-label, phase 2 trial
|
Jänne, Pasi A
|
|
2014
|
|
13 |
p. 1433-1441
|
artikel
|
| 45 |
Dasatinib and docetaxel in advanced prostate cancer
|
Lara Jr, Primo N
|
|
2013
|
|
13 |
p. 1248-1249
2 p.
|
artikel
|
| 46 |
28 days from referral to diagnosis in the UK: is it possible?
|
Burki, Talha Khan
|
|
2015
|
|
13 |
p. e485-
1 p.
|
artikel
|
| 47 |
Diagnostic performance of narrowed spectrum endoscopy, autofluorescence imaging, and confocal laser endomicroscopy for optical diagnosis of colonic polyps: a meta-analysis
|
Wanders, Linda K
|
|
2013
|
|
13 |
p. 1337-1347
11 p.
|
artikel
|
| 48 |
Dignity in death: the triumph of politics over evidence
|
The Lancet Oncology,
|
|
2013
|
|
13 |
p. 1243-
1 p.
|
artikel
|
| 49 |
Discordance between the results and conclusions of ICON7
|
Gyawali, Bishal
|
|
2015
|
|
13 |
p. e478-
1 p.
|
artikel
|
| 50 |
Discordance between the results and conclusions of ICON7 – Authors' reply
|
Oza, Amit M
|
|
2015
|
|
13 |
p. e478-e479
nvt p.
|
artikel
|
| 51 |
Disease kinetics for decision-making in advanced melanoma: a call for scenario-driven strategy trials
|
Grob, Jean Jacques
|
|
2015
|
|
13 |
p. e522-e526
nvt p.
|
artikel
|
| 52 |
Docetaxel and dasatinib or placebo in men with metastatic castration-resistant prostate cancer (READY): a randomised, double-blind phase 3 trial
|
Araujo, John C
|
|
2013
|
|
13 |
p. 1307-1316
10 p.
|
artikel
|
| 53 |
Docetaxel or pemetrexed with or without cetuximab in recurrent or progressive non-small-cell lung cancer after platinum-based therapy: a phase 3, open-label, randomised trial
|
Kim, Edward S
|
|
2013
|
|
13 |
p. 1326-1336
11 p.
|
artikel
|
| 54 |
Does cilengitide deserve another chance?
|
Tucci, Marco
|
|
2014
|
|
13 |
p. e584-e585
|
artikel
|
| 55 |
Does cilengitide deserve another chance?–Authors' reply
|
Stupp, Roger
|
|
2014
|
|
13 |
p. e585-e586
|
artikel
|
| 56 |
Dose-limiting toxicity and maximum tolerated dose: still fit for purpose?
|
Wong, Han Hsi
|
|
2015
|
|
13 |
p. 1287-1288
2 p.
|
artikel
|
| 57 |
Ductal carcinoma in situ and breast cancer mortality
|
Tanday, Sanjay
|
|
2015
|
|
13 |
p. e481-
1 p.
|
artikel
|
| 58 |
E-cigarettes and subsequent tobacco use in adolescence
|
Baker, Holly
|
|
2015
|
|
13 |
p. e481-
1 p.
|
artikel
|
| 59 |
Effect of adjuvant capecitabine or fluorouracil, with or without oxaliplatin, on survival outcomes in stage III colon cancer and the effect of oxaliplatin on post-relapse survival: a pooled analysis of individual patient data from four randomised controlled trials
|
Schmoll, Hans-Joachim
|
|
2014
|
|
13 |
p. 1481-1492
|
artikel
|
| 60 |
Effect of donor–recipient HLA matching at HLA A, B, C, and DRB1 on outcomes after umbilical-cord blood transplantation for leukaemia and myelodysplastic syndrome: a retrospective analysis
|
Eapen, Mary
|
|
2011
|
|
13 |
p. 1214-1221
8 p.
|
artikel
|
| 61 |
Electromotive administration of mitomycin
|
Ho, Christopher CK
|
|
2011
|
|
13 |
p. 1183-
1 p.
|
artikel
|
| 62 |
Endoscopic optical biopsy: when we look, what can we see?
|
Ladabaum, Uri
|
|
2013
|
|
13 |
p. 1253-1254
2 p.
|
artikel
|
| 63 |
Enterovirus infection and childhood leukaemia: an association?
|
Spector, Logan G
|
|
2015
|
|
13 |
p. 1278-1279
2 p.
|
artikel
|
| 64 |
Epidemiology, biology, and treatment of triple-negative breast cancer in women of African ancestry
|
Brewster, Abenaa M
|
|
2014
|
|
13 |
p. e625-e634
|
artikel
|
| 65 |
Erratum
|
|
|
2011
|
|
13 |
p. 1182-
1 p.
|
artikel
|
| 66 |
Erratum
|
|
|
2011
|
|
13 |
p. 1182-
1 p.
|
artikel
|
| 67 |
Everolimus for subependymal giant cell astrocytoma in patients with tuberous sclerosis complex: 2-year open-label extension of the randomised EXIST-1 study
|
Franz, David Neal
|
|
2014
|
|
13 |
p. 1513-1520
|
artikel
|
| 68 |
Evolving treatment options for melanoma brain metastases
|
Ajithkumar, Thankamma
|
|
2015
|
|
13 |
p. e486-e497
nvt p.
|
artikel
|
| 69 |
Expansion platform type II: testing a treatment strategy
|
Catenacci, Daniel V T
|
|
2015
|
|
13 |
p. 1276-1278
3 p.
|
artikel
|
| 70 |
Faith and medicine: goodbye cancer
|
Morgan, Jules
|
|
2014
|
|
13 |
p. 1431-1432
|
artikel
|
| 71 |
Fludarabine plus alemtuzumab versus fludarabine alone in patients with previously treated chronic lymphocytic leukaemia: a randomised phase 3 trial
|
Elter, Thomas
|
|
2011
|
|
13 |
p. 1204-1213
10 p.
|
artikel
|
| 72 |
Fluorouracil, epirubicin, and cyclophosphamide (FEC-75) followed by paclitaxel plus trastuzumab versus paclitaxel plus trastuzumab followed by FEC-75 plus trastuzumab as neoadjuvant treatment for patients with HER2-positive breast cancer (Z1041): a randomised, controlled, phase 3 trial
|
Buzdar, Aman U
|
|
2013
|
|
13 |
p. 1317-1325
9 p.
|
artikel
|
| 73 |
FOLFIRI with cetuximab or bevacizumab: FIRE-3
|
Pietrantonio, Filippo
|
|
2014
|
|
13 |
p. e581
|
artikel
|
| 74 |
FOLFIRI with cetuximab or bevacizumab: FIRE-3
|
Petrelli, Fausto
|
|
2014
|
|
13 |
p. e581-e582
|
artikel
|
| 75 |
FOLFIRI with cetuximab or bevacizumab: FIRE-3
|
Price, Timothy J
|
|
2014
|
|
13 |
p. e582-e583
|
artikel
|
| 76 |
FOLFIRI with cetuximab or bevacizumab: FIRE-3–Authors' reply
|
Heinemann, Volker
|
|
2014
|
|
13 |
p. e583-e584
|
artikel
|
| 77 |
FOLFOXIRI and bevacizumab in metastatic colorectal cancer
|
Rahman, Ahmadur
|
|
2014
|
|
13 |
p. e590
|
artikel
|
| 78 |
FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study
|
Cremolini, Chiara
|
|
2015
|
|
13 |
p. 1306-1315
10 p.
|
artikel
|
| 79 |
Global uptake of BHGI guidelines for breast cancer
|
Echavarria, Maria Isabel
|
|
2014
|
|
13 |
p. 1421-1423
|
artikel
|
| 80 |
HAND2 methylation linked to endometrial cancer
|
Bagcchi, Sanjeet
|
|
2013
|
|
13 |
p. e590-
1 p.
|
artikel
|
| 81 |
Harnessing GVHD by interleukin-6 receptor blockade
|
Finke, Jürgen
|
|
2014
|
|
13 |
p. 1411-1412
|
artikel
|
| 82 |
Hello. I have cancer. How are you?
|
Harding, Emilia
|
|
2015
|
|
13 |
p. 1294-
1 p.
|
artikel
|
| 83 |
High-dose re-irradiation following radical radiotherapy for non-small-cell lung cancer
|
De Ruysscher, Dirk
|
|
2014
|
|
13 |
p. e620-e624
|
artikel
|
| 84 |
Histone deacetylase inhibitors and Hodgkin's lymphoma
|
Kirschbaum, Mark H
|
|
2011
|
|
13 |
p. 1178-1179
2 p.
|
artikel
|
| 85 |
How can we improve adjuvant chemotherapy for colon cancer?
|
Boku, Narikazu
|
|
2014
|
|
13 |
p. 1413-1415
|
artikel
|
| 86 |
HPV vaccination not linked to miscarriage
|
Tanday, Sanjay
|
|
2015
|
|
13 |
p. e485-
1 p.
|
artikel
|
| 87 |
Infection control issues in patients with haematological malignancies in the era of multidrug-resistant bacteria
|
Ruhnke, Markus
|
|
2014
|
|
13 |
p. e606-e619
|
artikel
|
| 88 |
International Liver Cancer Association Annual Conference
|
Lokody, Isabel
|
|
2015
|
|
13 |
p. 1289-
1 p.
|
artikel
|
| 89 |
Intraoperative radiotherapy versus external radiotherapy for early breast cancer (ELIOT): a randomised controlled equivalence trial
|
Veronesi, Umberto
|
|
2013
|
|
13 |
p. 1269-1277
9 p.
|
artikel
|
| 90 |
Intrauterine device and cervical cancer: we need more evidence
|
Burgo, Cristina Lopez-del
|
|
2011
|
|
13 |
p. 1185-1186
2 p.
|
artikel
|
| 91 |
Intrauterine device and cervical cancer: we need more evidence – Authors' reply
|
Castellsagué, Xavier
|
|
2011
|
|
13 |
p. 1186-1187
2 p.
|
artikel
|
| 92 |
Is there a future for auto-allo HSCT in multiple myeloma?
|
Dispenzieri, Angela
|
|
2011
|
|
13 |
p. 1176-1177
2 p.
|
artikel
|
| 93 |
Is UK cancer care broken?
|
The Lancet Oncology,
|
|
2015
|
|
13 |
p. 1273-
1 p.
|
artikel
|
| 94 |
Lack of access to targeted cancer therapy
|
Burki, Talha Khan
|
|
2015
|
|
13 |
p. e482-
1 p.
|
artikel
|
| 95 |
Late detection of lung cancer
|
Burki, Talha Khan
|
|
2014
|
|
13 |
p. e590
|
artikel
|
| 96 |
Leucovorin, fluorouracil, and oxaliplatin plus bevacizumab versus S-1 and oxaliplatin plus bevacizumab in patients with metastatic colorectal cancer (SOFT): an open-label, non-inferiority, randomised phase 3 trial
|
Yamada, Yasuhide
|
|
2013
|
|
13 |
p. 1278-1286
9 p.
|
artikel
|
| 97 |
Life Itself
|
van Dorn, Aaron
|
|
2014
|
|
13 |
p. 1429-1430
|
artikel
|
| 98 |
Locoregional treatment versus no treatment of the primary tumour in metastatic breast cancer: an open-label randomised controlled trial
|
Badwe, Rajendra
|
|
2015
|
|
13 |
p. 1380-1388
9 p.
|
artikel
|
| 99 |
Maintenance strategies after first-line oxaliplatin plus fluoropyrimidine plus bevacizumab for patients with metastatic colorectal cancer (AIO 0207): a randomised, non-inferiority, open-label, phase 3 trial
|
Hegewisch-Becker, Susanna
|
|
2015
|
|
13 |
p. 1355-1369
15 p.
|
artikel
|
| 100 |
Maintenance therapy for metastatic colorectal cancer
|
Giampieri, Riccardo
|
|
2015
|
|
13 |
p. 1281-1282
2 p.
|
artikel
|
| 101 |
Me and Earl and the Dying Girl
|
Cleghorn, Sean
|
|
2015
|
|
13 |
p. 1292-1293
2 p.
|
artikel
|
| 102 |
Meningiomas in children and adolescents: a meta-analysis of individual patient data
|
Kotecha, Rishi S
|
|
2011
|
|
13 |
p. 1229-1239
11 p.
|
artikel
|
| 103 |
Mistletoe: for cancer or just for Christmas?
|
de Giorgio, Alex
|
|
2013
|
|
13 |
p. 1264-1265
2 p.
|
artikel
|
| 104 |
Mocetinostat for relapsed classical Hodgkin's lymphoma: an open-label, single-arm, phase 2 trial
|
Younes, Anas
|
|
2011
|
|
13 |
p. 1222-1228
7 p.
|
artikel
|
| 105 |
Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial
|
Le Tourneau, Christophe
|
|
2015
|
|
13 |
p. 1324-1334
11 p.
|
artikel
|
| 106 |
Mondays at Racine
|
van Dorn, Aaron
|
|
2013
|
|
13 |
p. 1267-
1 p.
|
artikel
|
| 107 |
MRI study identifies three subtypes of glioblastoma
|
Brower, Vicki
|
|
2015
|
|
13 |
p. e484-
1 p.
|
artikel
|
| 108 |
Mutation and location important in cancer treatment
|
Lewis, Ricki
|
|
2015
|
|
13 |
p. e482-
1 p.
|
artikel
|
| 109 |
Mutations in chondroblastoma and giant cell tumour of bone
|
Yaqub, Farhat
|
|
2013
|
|
13 |
p. e587-
1 p.
|
artikel
|
| 110 |
Nab-paclitaxel shows promise in pancreatic cancer
|
Baker, Holly
|
|
2013
|
|
13 |
p. e585-
1 p.
|
artikel
|
| 111 |
NCRI Cancer Conference
|
Smith, Lan-Lan
|
|
2013
|
|
13 |
p. 1261-
1 p.
|
artikel
|
| 112 |
2011 NCRI conference
|
Sansom, Clare
|
|
2011
|
|
13 |
p. 1189-
1 p.
|
artikel
|
| 113 |
Neonatal cancer
|
Orbach, Daniel
|
|
2013
|
|
13 |
p. e609-e620
nvt p.
|
artikel
|
| 114 |
New immunotherapy on horizon for melanoma?
|
Sharma, Sharan Prakash
|
|
2013
|
|
13 |
p. e586-
1 p.
|
artikel
|
| 115 |
NICE guidance on dabrafenib for treating unresectable or metastatic BRAF V600 mutation-positive melanoma
|
Tucker, Helen
|
|
2014
|
|
13 |
p. 1425-1426
|
artikel
|
| 116 |
Nine letters
|
Wilcken, Nicholas
|
|
2011
|
|
13 |
p. 1193-1194
2 p.
|
artikel
|
| 117 |
Nocebo side-effects in cancer treatment
|
Garg, Amit K
|
|
2011
|
|
13 |
p. 1181-1182
2 p.
|
artikel
|
| 118 |
No increase in overall cancer risk from assisted conception
|
Baker, Holly
|
|
2013
|
|
13 |
p. e589-
1 p.
|
artikel
|
| 119 |
Non-coding RNAs as biomarkers for metastatic prostate cancer
|
Veltri, William Robert
|
|
2014
|
|
13 |
p. 1412-1413
|
artikel
|
| 120 |
Not quite falling off a cliff
|
Morgan, Jules
|
|
2014
|
|
13 |
p. 1431
|
artikel
|
| 121 |
Ofatumumab maintenance versus observation in relapsed chronic lymphocytic leukaemia (PROLONG): an open-label, multicentre, randomised phase 3 study
|
van Oers, Marinus H J
|
|
2015
|
|
13 |
p. 1370-1379
10 p.
|
artikel
|
| 122 |
Older people not likely to refuse cancer treatment
|
Bagcchi, Sanjeet
|
|
2015
|
|
13 |
p. e483-
1 p.
|
artikel
|
| 123 |
One dose of HPV vaccine may suffice
|
Tanday, Sanjay
|
|
2013
|
|
13 |
p. e588-
1 p.
|
artikel
|
| 124 |
Ovarian transposition in prepubescent and adolescent girls with cancer
|
Irtan, Sabine
|
|
2013
|
|
13 |
p. e601-e608
nvt p.
|
artikel
|
| 125 |
PD-L1 expression as a potential predictive biomarker
|
Fusi, Alberto
|
|
2015
|
|
13 |
p. 1285-1287
3 p.
|
artikel
|
| 126 |
Pelvic inflammatory disease and ovarian cancer
|
van de Laar, R
|
|
2011
|
|
13 |
p. 1184-
1 p.
|
artikel
|
| 127 |
Pelvic inflammatory disease and ovarian cancer
|
Cheong, Kelby M
|
|
2011
|
|
13 |
p. 1183-1184
2 p.
|
artikel
|
| 128 |
Pelvic inflammatory disease and ovarian cancer – Authors' reply
|
Lin, Hui-Wen
|
|
2011
|
|
13 |
p. 1184-1185
2 p.
|
artikel
|
| 129 |
Personalised chemotherapy based on tumour marker decline in poor prognosis germ-cell tumours (GETUG 13): a phase 3, multicentre, randomised trial
|
Fizazi, Karim
|
|
2014
|
|
13 |
p. 1442-1450
|
artikel
|
| 130 |
Perspectives on breast cancer in Arab populations
|
Corbex, Marilys
|
|
2013
|
|
13 |
p. e582-
1 p.
|
artikel
|
| 131 |
Pitfalls in extrapolating adult data to rare paediatric diseases
|
Traunecker, Heidi
|
|
2011
|
|
13 |
p. 1180-1181
2 p.
|
artikel
|
| 132 |
Polypharmacy in elderly patients with cancer: clinical implications and management
|
Lees, Judith
|
|
2011
|
|
13 |
p. 1249-1257
9 p.
|
artikel
|
| 133 |
Ponatinib: hope for patients with CML or Ph-positive ALL?
|
Yaqub, Farhat
|
|
2013
|
|
13 |
p. e588-
1 p.
|
artikel
|
| 134 |
Predicting pathological complete response in breast cancer early
|
Groheux, David
|
|
2014
|
|
13 |
p. 1415-1416
|
artikel
|
| 135 |
Prevention of CNS relapse in diffuse large B-cell lymphoma
|
Kridel, Robert
|
|
2011
|
|
13 |
p. 1258-1266
9 p.
|
artikel
|
| 136 |
Prognostic and predictive value of a microRNA signature in stage II colon cancer: a microRNA expression analysis
|
Zhang, Jia-Xing
|
|
2013
|
|
13 |
p. 1295-1306
12 p.
|
artikel
|
| 137 |
PROLONGing remissions in patients with CLL
|
Wiestner, Adrian
|
|
2015
|
|
13 |
p. 1282-1284
3 p.
|
artikel
|
| 138 |
Prostate cancer services vary in England and Wales
|
Mayor, Susan
|
|
2014
|
|
13 |
p. e593
|
artikel
|
| 139 |
PSA test not recommended by Canadian Task Force
|
Tanday, Sanjay
|
|
2014
|
|
13 |
p. e589
|
artikel
|
| 140 |
Psychological effect of breast cancer
|
Galgut, Cordelia
|
|
2011
|
|
13 |
p. 1187-
1 p.
|
artikel
|
| 141 |
Psychological morbidity and quality of life of ethnic minority patients with cancer: a systematic review and meta-analysis
|
Luckett, Tim
|
|
2011
|
|
13 |
p. 1240-1248
9 p.
|
artikel
|
| 142 |
Radiation and checkpoint blockade immunotherapy: radiosensitisation and potential mechanisms of synergy
|
Sharabi, Andrew B
|
|
2015
|
|
13 |
p. e498-e509
nvt p.
|
artikel
|
| 143 |
Radiotherapy for testicular cancer increases gastric cancer risk
|
Bagcchi, Sanjeet
|
|
2014
|
|
13 |
p. e593
|
artikel
|
| 144 |
Recommendations for breast cancer surveillance for female survivors of childhood, adolescent, and young adult cancer given chest radiation: a report from the International Late Effects of Childhood Cancer Guideline Harmonization Group
|
Mulder, Renée L
|
|
2013
|
|
13 |
p. e621-e629
nvt p.
|
artikel
|
| 145 |
Regulatory and clinical considerations for biosimilar oncology drugs
|
Bennett, Charles L
|
|
2014
|
|
13 |
p. e594-e605
|
artikel
|
| 146 |
Removing the primary tumour in metastatic breast cancer
|
Cameron, David
|
|
2015
|
|
13 |
p. 1284-1285
2 p.
|
artikel
|
| 147 |
Reproducing our species and finding solutions
|
Halperin, Edward C
|
|
2013
|
|
13 |
p. 1256-1258
3 p.
|
artikel
|
| 148 |
Risk of death among children of atomic bomb survivors after 62 years of follow-up: a cohort study
|
Grant, Eric J
|
|
2015
|
|
13 |
p. 1316-1323
8 p.
|
artikel
|
| 149 |
Risk of leukaemia in children infected with enterovirus: a nationwide, retrospective, population-based, Taiwanese-registry, cohort study
|
Lin, Jiun-Nong
|
|
2015
|
|
13 |
p. 1335-1343
9 p.
|
artikel
|
| 150 |
RNA biomarkers associated with metastatic progression in prostate cancer: a multi-institutional high-throughput analysis of SChLAP1
|
Prensner, John R
|
|
2014
|
|
13 |
p. 1469-1480
|
artikel
|
| 151 |
Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: an open-label phase 1/2 study
|
Kumar, Shaji K
|
|
2014
|
|
13 |
p. 1503-1512
|
artikel
|
| 152 |
S-1: another oral agent for patients with colorectal cancer
|
Benson III, Al B
|
|
2013
|
|
13 |
p. 1244-1245
2 p.
|
artikel
|
| 153 |
Screw You Cancer
|
Clague, Stephanie
|
|
2013
|
|
13 |
p. 1265-1266
2 p.
|
artikel
|
| 154 |
Self-referral for IMRT in prostate cancer treatment
|
Burki, Talha Khan
|
|
2013
|
|
13 |
p. e586-
1 p.
|
artikel
|
| 155 |
Should oncologists support the Affordable Care Act?
|
Kantarjian, Hagop
|
|
2013
|
|
13 |
p. 1258-1259
2 p.
|
artikel
|
| 156 |
Should we worry about inherited radiation risks?
|
Brenner, David J
|
|
2015
|
|
13 |
p. 1275-1276
2 p.
|
artikel
|
| 157 |
Tapping our immune potential to realise the ultimate goal
|
The Lancet Oncology,
|
|
2011
|
|
13 |
p. 1175-
1 p.
|
artikel
|
| 158 |
Targeting brain metastases in ALK-rearranged non-small-cell lung cancer
|
Zhang, Isabella
|
|
2015
|
|
13 |
p. e510-e521
nvt p.
|
artikel
|
| 159 |
12th AACR Frontiers in Cancer Prevention Research meeting
|
McLarnon, Andy
|
|
2013
|
|
13 |
p. e587-
1 p.
|
artikel
|
| 160 |
The beginning after the end
|
Collett, John
|
|
2013
|
|
13 |
p. 1267-1268
2 p.
|
artikel
|
| 161 |
The carcinogenicity of outdoor air pollution
|
Loomis, Dana
|
|
2013
|
|
13 |
p. 1262-1263
2 p.
|
artikel
|
| 162 |
The great divide in cancer care continues to fail Aborigines
|
Kenyon, Georgina
|
|
2011
|
|
13 |
p. 1188-
1 p.
|
artikel
|
| 163 |
The Iceberg
|
Russill, Katherine
|
|
2014
|
|
13 |
p. 1430-1431
|
artikel
|
| 164 |
The mTOR inhibitor revolution rolls on
|
Northrup, Hope
|
|
2014
|
|
13 |
p. 1418-1419
|
artikel
|
| 165 |
15th IASLC World Conference on Lung Cancer
|
Brierley, Rob
|
|
2013
|
|
13 |
p. 1260-
1 p.
|
artikel
|
| 166 |
16th World Conference on Lung Cancer
|
Landman, Allison
|
|
2015
|
|
13 |
p. 1290-
1 p.
|
artikel
|
| 167 |
Till death do us part
|
Rousseau, Paul
|
|
2011
|
|
13 |
p. 1192-1193
2 p.
|
artikel
|
| 168 |
Time for evidence-based e-cigarette regulation
|
Polosa, Riccardo
|
|
2013
|
|
13 |
p. e582-e583
nvt p.
|
artikel
|
| 169 |
Time to abandon traditional chemotherapy for acute promyelocytic leukaemia?
|
Ravandi, Farhad
|
|
2015
|
|
13 |
p. 1274-1275
2 p.
|
artikel
|
| 170 |
Tongue cancers not associated with tobacco in Chennai
|
Sharma, Dinesh C
|
|
2013
|
|
13 |
p. e590-
1 p.
|
artikel
|
| 171 |
Treatment of HER2-positive breast cancer: looking backwards briefly
|
Puhalla, Shannon
|
|
2013
|
|
13 |
p. 1250-1251
2 p.
|
artikel
|
| 172 |
Tumour genomic and microenvironmental heterogeneity for integrated prediction of 5-year biochemical recurrence of prostate cancer: a retrospective cohort study
|
Lalonde, Emilie
|
|
2014
|
|
13 |
p. 1521-1532
|
artikel
|
| 173 |
Use of [18F]-FDG PET to predict response to neoadjuvant trastuzumab and docetaxel in patients with HER2-positive breast cancer, and addition of bevacizumab to neoadjuvant trastuzumab and docetaxel in [18F]-FDG PET-predicted non-responders (AVATAXHER): an open-label, randomised phase 2 trial
|
Coudert, Bruno
|
|
2014
|
|
13 |
p. 1493-1502
|
artikel
|
| 174 |
US hospitals object to changes in Genentech drug distribution
|
Furlow, Bryant
|
|
2014
|
|
13 |
p. e591
|
artikel
|
| 175 |
Vemurafenib for relapsed or refractory hairy-cell leukaemia
|
Baker, Holly
|
|
2015
|
|
13 |
p. e484-
1 p.
|
artikel
|
| 176 |
Vintafolide combination for ovarian cancer
|
Gilbert, Judith A
|
|
2013
|
|
13 |
p. e585-
1 p.
|
artikel
|
| 177 |
Ways to Live Forever
|
Hill, Emma
|
|
2013
|
|
13 |
p. 1266-
1 p.
|
artikel
|
| 178 |
What We Did On Our Holiday
|
Mohammadi, Dara
|
|
2014
|
|
13 |
p. 1429
|
artikel
|
| 179 |
WHO Framework Convention on Tobacco Control conference
|
Burki, Talha Khan
|
|
2014
|
|
13 |
p. e588
|
artikel
|
Tijdschrift beschrijving